RVMD FY 2021 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M-31.6% YoY

Gross Profit

$29M100.0% margin

Operating Income

-$188M-639.7% margin

Net Income

-$187M-636.6% margin

EPS (Diluted)

$-2.47

Cash Flow

Operating Cash Flow

-$147M

Free Cash Flow

-$154M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$738M

Total Liabilities

$135M

Stockholders' Equity

$603M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$43M	-31.6%
Gross Profit	$29M	$43M	-31.6%
Operating Income	-$188M	-$111M	-69.8%
Net Income	-$187M	-$108M	-73.0%